Chromosomal Aberrations in Blood Lymphocytes as Predictors of Respiratory Function After Stereotactic Lung Irradiation

Zsuzsa S. Kocsis1, Gyöngyi Farkas1, András Bajcsay1, Márta Kun-Gazda1, József Lövey2,3, Gyula Ostoros4, Tamás Pócza2, András Herein2, Katalin Ladányi2, Gábor Székely1, Zsolt Markóczy4, Zoltán Takácsi-Nagy2,3*, Csaba Polgár2,3 and Zsolt Jurányi1,3

1 Department of Radiobiology and Diagnostic Onco-Cytogenetics, Centre of Radiotherapy, National Institute of Oncology, Budapest, Hungary, 2 Centre of Radiotherapy, National Institute of Oncology, Budapest, Hungary, 3 Semmelweis University, Faculty of Medicine, Department of Oncology, Budapest, Hungary, 4 National Korányi Institute of Pulmonology, Budapest, Hungary

Due to the profound difference in radiosensitivity of patients and various side effects caused by this phenomenon, a radiosensitivity marker is needed. Prediction by a marker may help personalise the treatment. In this study, we tested chromosomal aberrations (CA) of in vitro irradiated blood as predictor of pulmonary function decrease of nonsmall cell lung cancer (NSCLC) patients and also compared it with the CAs in the blood of irradiated patients. Peripheral blood samples were taken from 45 lung cancer patients before stereotactic radiotherapy (SBRT) and immediately after the last fraction and 3, 6, 9, 12, 15, 18, 21, and 24 months later. Respiratory function measurements were performed at the same time. Diffusing capacity of lung for carbon monoxide (DLCO), forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1s), and FEV1s/FVC (FEV1%) were monitored. Metaphase preparations of lymphocytes were made with standard procedures, and chromosome aberrations were analysed. In our cohort, the 36-month local relapse-free survival was 97.4%, and the distant metastasis-free survival was 71.5% at 36 months. There was no change in the mean of the pulmonary function tests (PFTs) after the therapy. However, there was a considerable variability between the patients. Therefore, we subtracted the baseline and normalised the PFT values. There were significant decreases at 12–24 months in relative FEV1s and relative FEV1%. The tendentious decrease of the PFTs could be predicted by the in vitro chromosome aberration data. We also found connections between the in vitro and in vivo CA values (i.e., dicentrics plus rings after 3 Gy irradiation predicts dicentric-plus-ring value directly after the radiotherapy/V54 Gy (p = 0.001 24.2%)). We found that—after further validation—chromosome aberrations resulted from in vitro irradiation before radiotherapy can be a predictive marker of pulmonary function decrease after lung irradiation.

Keywords: SABRT, radiotherapy, lung cancer, pulmonary function tests, chromosomal aberrations, radiosensitivity, SBRT
**INTRODUCTION**

Radiotherapy is a crucial modality for treating lung cancer, which still leads the morbidity and mortality statistics worldwide. Although surgical resection is the standard of care for stages I–II nonsmall cell lung cancer (NSCLC) (1, 2), a high percentage of these patients are inoperable due to comorbidities, mostly chronic obstructive pulmonary disease (COPD) (3–5). Therefore, stereotactic body radiotherapy (SBRT) has an emerging role in the treatment of patients with medically inoperable tumours. Compared with standard radiation, stereotactic body radiation therapy (SBRT) offers larger fractions, smaller field, and shorter, therefore, more favourable overall treatment time (6, 7).

On the other hand, there may be large volumes irradiated with low dose (especially at arc radiation techniques) compared with standard radiotherapy which raised questions of possible pulmonary function decrease. Accordingly, SBRT seems to be better tolerated at population level in the medically inoperable patient group, but the diffusing capacity of the lung carbon monoxide (DLCO) or forced vital capacity (FVC) results are controversial (8–10). The cause might be that the average lung function values after SBRT of the whole patient group may not change, but the individuals may exhibit significant increases or decreases. Stephens et al., for example, found that 10% of the patients experienced at least 14.8% decline in FEV1%, while another 10% experienced an increase of at least 12.7% (11). They also showed similar DLCO variability. The extreme differences and possible unexpected severe radiogenic toxicities can be caused by the individual radiosensitivity just as in the case of every radiotherapy (12). To judge the risk of pulmonary fibrosis, the baseline clinical and treatment planning data, such as tumour volume, stage, and isodose volumes may not be enough (13).

Therefore, the main objective of predictive radiosensitivity testing is to screen candidates in order to pinpoint patients at risk (14–18). The relationship between radiation therapy-related side effects and frequencies of chromosomal aberrations (CAs) has already been correlated to individual radiosensitivity in former publications; however, there was no consensus in the results (19–22). The method is very cheap and robust; therefore, it can be a considerable choice beside genetic tests. It was suggested that this correlation can be later used in the clinical practice (23). Micronucleus method is a highly similar method and is also suggested as a predictive biomarker in clinical studies; however, its results are similarly contradictory (24–28).

In our study, we compared chromosomal aberrations in vitro and ex vivo before and after irradiation treatments and follow-up in patients. We tested whether the chromosomal radiosensitivity of in vitro-irradiated lymphocytes (3 and 6 Gy) could be used to predict the risk of decrease in pulmonary functions (FVC, DLCO) after radiotherapy of lung cancer patients.

**METHODS**

**Patients**

This study was approved by the Hungarian Ethical Committee, ETT TUKEB (23546-3/2017/EKU) and was conducted following the principles of the Helsinki Declaration. All subjects were informed about the aim of the study and gave their written consent to participate.

We enrolled 45 patients between January 2016 and February 2019. Tumours with a diameter below 3 cm were treated, but the TNM status was diverse: 68.9% of the patients had T1 tumour and 15.6% T2 tumour; the others had T4 (4.4%) or tumour not staged. We also treated two metastases, which were the disseminations of a gastrointestinal and a renal primary tumour. These were excluded from survival analysis but included in CA and pulmonary function test (PFT) evaluation.

**Treatment Procedure**

Patients were treated with stereotactic body radiation therapy based on the 4D-CT with 3 mm slice thickness taken in free breath mode. Critical structures, including spinal cord, heart, brachial plexus, and oesophagus were outlined, and dose constraints are used according to accepted standards (29) (Supplementary Table S1). Combining the gross target volume (GTVs) (determined by contouring the macroscopic tumour using lung window) in seven respiratory positions without extension, internal target volume (ITV) was generated. Planning target volume (PTV) was produced by the 0.6-cm extension of the ITV. An eighth, average CT reconstruction was also generated and used for dose calculation and optimisation. Forty-two patients were treated with 8 × 7.5 Gy, and three patients were treated with 5 × 12 Gy. We used volumetric modulated arc therapy (VMAT) technique, 6 MV accelerator energy with flattening filter free (FFF) mode and 1,400 MU/min dose rate. We used Varian Eclipse 13.7 planning system (AAA calculation algorithm) and TrueBeam linear accelerator.

**Lymphocyte Culture and Chromosome Aberrations**

Before radiotherapy, immediately after the irradiation, and later every 3 months, 10 ml of blood was drawn from the patients. The 3- or 6-Gy in vitro irradiation of blood taken before the therapy was performed under the same conditions (1,400 MU/min, 6 FFF) as the radiotherapy. The irradiation was executed in a water phantom in cryotubes positioned in the isocenter (the bottom of the cryotube was 4 cm below the surface of the water). The lymphocyte cultures were induced to proliferate with phytohaemagglutinin M (2% v/v; Gibco, Waltham, MA, USA). Both the in vitro-irradiated and nonirradiated blood samples were cultured by standard cytogenetic techniques in cell culture medium (RPMI-1640, 15% bovine serum albumin; 100 U/ml penicillin, 100 µg/ml streptomycin) for 48 h. For arresting cells in metaphase, the cultures were incubated with 0.1 µg/ml Colcemid (Gibco) for two more hours. Cell cultures were treated with hypotonic solution (0.075 M KCl) for 15 minutes at 37°C; the fixation step was repeated with cold methanol-acetic acid five times (3:1). The cell suspension was dropped on glass slides, dried, and stained with 3% Giemsa dye.

**Analysis of Chromosomal Aberrations**

At least 100 metaphases/sample were analysed with 1,500× magnification by two experienced analysers and customary
given as aberration/100 cells. The following aberrations were evaluated: chromatid breaks, exchanges, chromosome fragments, dicentrics, rings, and translocations (which was distinguishable with Giemsa staining). One dicentric or ring (centric and acentric) and their associated fragment were counted together as one aberration. Excess terminal and interstitial deletions are summed up and analysed as “chromosome fragments”. The total aberration count is the sum of these values, while aberrant cell value is the number of cells with any aberration. We applied the requirements of the ICPEMC (30) guideline.

Pulmonary Function Tests
We analysed DLCO and FVC before radiotherapy, directly after the last fraction and 3, 6, 9, 12, 15, 18, 24, and 36 months after the therapy within 1 week after the blood draw. We calculated relative changes by subtracting baseline value from the actual data and dividing the difference with the baseline value.

Statistical Analysis
The chromosomal aberration values and yields of aberrant cells were given per 100 cells, as customary. As the distribution of aberration values differ from the normal distribution, Mann-Whitney test was performed to analyse differences between CAs. We performed univariate regression analysis to compare CA values of in vitro-irradiated blood and PFT values. This method was also applied to connect in vitro and in vivo CA values. Outliers were detected by ROUT method in GraphPad Prism 8 (San Diego, CA, USA) (31). We did not consider data series with less than fifteen cases. (The first patient was excluded from in vitro CA analysis as the irradiation was performed under slightly different conditions as the irradiation of the other blood samples.) The p-value of <0.05 was considered significant in every test. Survival functions were analysed using Kaplan-Meier curves. For data analysis and presentation, Minitab 18.1, OriginPro 8.5, and IBM SPSS statistics 25.0 software packages were used.

RESULTS
Epidemiology
We recruited 45 patients (Table 1) between 52 and 84 years of age. There was a female predominance. Most patients (92.8%) had a history of smoking, and COPD was a comorbidity in 77.8%. Median DLCO was 48.8%, and the mean FVC was 84.9%.

Treatment Efficacy, Survival Curves
For all patients, the local relapse-free survival was 97.4% at 36 months, and the regional relapse-free survival was similarly favourable (93.6%) (Supplementary Figures S1A, B). On the other hand, we observed 71.5% distant metastasis-free survival (median was 40 months (35.9–44.1 95% CI)), which characterises the disease more than it describes the effectivity of the radiotherapy (Supplementary Figure S1C). However, 84.2% of the patients did not need any other treatment for 3 years (Supplementary Figure S1D). The 3-year lung cancerspecific survival was 83.6%, and due to the comorbidities, the overall survival was 68.9% (Supplementary Figures S1E, F).

| Characteristic                  | Value                                      |
|---------------------------------|--------------------------------------------|
| Median age (range)              | 69 years (52–84)                           |
| Gender: female/male             | 25/20 (55.6% vs. 44.4%)                    |
| Stage                           |                                            |
| T1, T2                          | 32/9                                       |
| T4*, T6                        | 2/2                                        |
| Histology                       |                                            |
| Plane cell                     | 3                                          |
| Adenocarcinoma                  | 9                                          |
| Other, poorly diff.             | 1                                          |
| No biopsy, PET/CT               | 32                                         |
| Smoking status (no information for 3 patients) | 3 (7.1%)                                 |
| History of smoking: never       | 10/29 (92.8%)                              |
| Pulmonary function (mean ± SD)  |                                            |
| FVC (%)                         | 84.9 ± 19.8                                |
| DLCO (as % of predicted)        | 48.8 ± 21.9                                |
| FEV1 (%)                        | 68.4 ± 25.3                                |
| FEV1/L (L)                      | 1.6 ± 0.6                                  |
| COPD/non-COPD                   | 35/10                                      |
| Treatment                       |                                            |
| 8 × 7.5 Gy                     | 42                                         |
| 5 × 12 Gy                      | 3                                          |

*Multifocal tumour or second tumour on the contralateral side.

Chromosomal Aberrations In Vitro
In order to assess the predictive power of the chromosome aberration method, we irradiated the blood samples taken before the therapy with 3 and 6 Gy under the same conditions as patients were treated (dose rate, photon energy) (Supplementary Table S2). (One part of the sample served as unirradiated control to detect possible chromosomal aberrations present before the beginning of the therapy). We also compared the determined CAs with the historical controls of healthy volunteers (N = 3 mean age: 36.3) (Supplementary Table S2).

The mean values of aberrations did not differ for the patient group and the healthy volunteer group. There were 76.0 ± 2.7 vs. 73.7 ± 3.9 total aberrations/100 cells after 3 Gy irradiation and 260.9 ± 7.7 vs. 302.7 ± 13.0 total aberrations/100 cells resulted from 6 Gy in vitro radiation (Supplementary Figure S2). The patients treated with SBRT in our study were not exceptionally radiosensitive. We also could not identify any outlier radiosensitivity in the treatment group based on CA values after in vitro irradiation.

Chromosomal Aberrations of Patients After Radiotherapy
We followed the change of chromosomal aberrations in patients after the radiotherapy. The values measured directly after the SBRT can be used to estimate the biological dose, and the samples collected during the follow-up indicate the elimination of radiogenic damage from the blood, which is considered surrogate of the normal tissue toxicities. We observed a 4.8-fold change in the radiospecific dicentric+ring aberrations (from 1.1 ± 0.2 to 5.3 ± 0.6/100 cells, p < 0.0001) (Figure 1A) and a 3.3-fold total aberration value change (from 3.9 ± 0.5 to 13.0 ± 1.2/100 cells, p < 0.0001) after radiotherapy (Figure 1B; Supplementary Table S2). The first significant decrease
(compared with the value directly after radiotherapy) in the aberration values was seen at 21 months after the radiotherapy. There is an increase in CAs at 30 months after radiotherapy, but it is not significant and can be caused by the insufficient number of data points at this time point. In the case of chromosome fragments, the values at 3 years are similar to the ones recorded directly after radiotherapy. The reason for this can be the statistical uncertainty or the damaged lymphocytes—after a period of time—reenter blood circulation from lymph nodes. The CAs did not decrease to the baseline level even 3 years after the radiotherapy.

Changes of Pulmonary Function Tests After Stereotactic Body Radiotherapy

We compared the mean of the DLCO, FVC, FEV1s, and FEV1% data before and after SBRT therapy (directly and 3, 6, 9, 12, 15, 18, 21, and 24 months after the therapy) and found no significant difference between them.

On the other hand, COPD as a comorbidity can alter baseline pulmonary function data and cause substantial differences between the patients. Therefore, we calculated relative pulmonary function change values: \( \frac{\text{PFT}_{\text{time point}} - \text{PFT}_{\text{baseline}}}{\text{PFT}_{\text{baseline}}} \). There was no significant change between the relative DLCO and FVC alterations directly after radiotherapy and at time points during the follow-up (Figures 2A, B). However, there were substantial differences between the patients. The FVC relative increase at 3 months, for example, is between 0% and 10% for the 43.8% and between 10% and 20% for 3.1% of the patients, respectively. At the same time point, there is a 0%–10% decrease for 34.4%; 10%–20% for 12.5%, and 20%–30% for 6.2% of the patients, respectively. However, the average values are negative, showing pulmonary function decrease.

Both the FEV1s and FEV1% relative changes show significant decrease after 12, 15, 18, and 21 months, but there is no difference after 2 years (Figures 2C, D). We could not perform any subgroup analysis of the effect of COPD as there were only ten non-COPD patients (20.4%) in our cohort.

Relationship Between In Vitro Chromosomal Aberrations and Pulmonary Function Values of the Patients

We compared the chromosome aberrations measured before radiotherapy in the case of patients who later showed more than 20% of decrease in pulmonary function (at any of the time points) and in the case of those with less decrease (including patients with improving PFTs). There was no significant difference (Mann-Whitney U test) in the chromosome aberrations of the patients with at least 20% and of those with less FEV1 decrease. However, we found more dicentrics+rings in the samples irradiated with 3 Gy prior to radiotherapy of patients whose FVC \( (p = 0.010) \) or FEV1% \( (p = 0.038) \) later decreased by at least 20% (Figures 3A, B). Furthermore, patients with at least 20% decrease in DLCO had significantly more chromosome breaks \( (p = 0.037) \) after 3 Gy, and total aberrations \( (p = 0.009) \) and aberrant cells \( (p = 0.012) \) after 6 Gy in vitro irradiation (Figures 3C–E).

We found only one case when the dicentrics plus rings frequency was significantly higher in patients with a severe FEV1% decrease than this CA value of healthy donors \( (p = 0.048) \) (Mann-Whitney two-tailed \( t \)-test). Chromosome
The fragment value was also significantly lower in patients with no/slight FEV1 decrease than healthy controls ($p = 0.049$).

We analysed the predictive capacity of chromosome aberrations on pulmonary function by performing univariate regression analysis. There were twelve significant models (Supplementary Table S3). All the regression coefficients are negative: the more chromosome aberrations generated (by in vitro irradiation) in the blood taken before radiotherapy, the more lung function decrease was seen in the patients (example in Figure 4). Approximately 19%–35% ($R^2$) of the pulmonary function variance can be explained by the change of the chromosome aberrations of in vitro-irradiated blood. The DLCO and FEV1% values were predicted in the majority of the models. Furthermore, chromosome aberrations after 3 Gy irradiation were predictors in as many models as CAs after 6 Gy irradiation.

**DISCUSSION**

The treatment of primary lung cancer with SBRT is proved to result in exceptional local progression-free survival (LPFS). The LPFS at 2 years was 64%–96% and 52%–95% at 3 years in large cohorts. A European study demonstrated even more than 90% local control at 3 years for a regime of 60 Gy in eight fractions (32). The overall survival was between 52% and 87% at 2 years, and between 43% and 75% at 3 years. SBRT increased 3-year overall survival by 14%–30% compared with conventional radiotherapy in NSCLC (7, 33). Our result of overall (68.9% at 36 months) and lung cancer-specific survival (83.6% at 36 months) (Supplementary Figure S1) are in line with the meta-analysis of Prezzano et al. who described a 43%–95% overall survival at 3 years and local control even as high as 98% (34).

Meanwhile, severe ($\geq$ grade 3) side effects in a wide variety of studies occurred in 0%–3% (mostly CTCAE graded) (35–38). On the other hand, there were controversial results of change in pulmonary function after lung radiotherapy. Ohashi et al., for example, described no change in FEV1 and an increase in DLCO in a small population of Japanese patients (8). However, Henderson...
et al. observed 1.11 ml/min/mmHg/year DLCO decrease in 70 patients (9). COPD also affected the change of DLCO in the thirty-patient cohort of Bishawi et al. They found an increase of DLCO in patients without COPD ($p = 0.022$), but no change in the subgroup suffering from COPD (39). In another study, FEV1s decreased by 5.8% and DLCO was reduced by 6.3% at 2 years (10). FEV1 and FVC difference were also recorded in patients free of COPD (7.9% and 5.9%, respectively) (40). Comparing individuals, a minimum of 19.4% DLCO decrease found in 10% of the patients and at least 18% increase was found in another 10% of the patients by Stephans et al. (11). We could not find any significant difference between the absolute PFT results before therapy and at any other time points. On the other hand, there was a substantial difference between the patients. We observed even 20%–30% changes in approximately 5% of the patients at certain time points. The occasional increase might be explained by the shrinking of tumours, which previously obstructed airways or vessels.

One of the limitations of our study is this large difference between the PFT patients. Unfortunately, the number of patients was also limited. Therefore, to equilibrate the interpersonal variability of the baseline PFTs, we applied relative change values: baseline subtracted from the PFT value of the time point and normalised with the baseline data. The relative changes of all types of pulmonary function test show decrease after the SBRT (Figure 2). However, there is no significant change between the time points except in the FEV1 data after 12 months. There was a tendency of greater loss of pulmonary function after 3 months measured with DLCO, which resolved later. At the same time, there was a tendentious steady decrease in FVC and FEV1 values (Figure 2). The decrease of FVC and FEV1 could be attributable to the worsening of the COPD disease or continuing smoking (in 77.7% and 22.2% of the patients, respectively). DLCO value is less affected by obstructive conditions and might indicate the temporary effect of the radiotherapy.

Identification of patients with extreme radiosensitivity with in vitro tests would reduce the frequency of severe side effects and healthcare cost as well. The possibility of evaluation of radiosensitivity with biodosimetric methods was previously studied. For instance, the number of lethal defects in the lymphocytes after the irradiation of blood taken from patients prior to radiotherapy may also be related to the risk of fibrosis (19). The frequency of chromosome aberrations in
peripheral blood taken from breast cancer patients revealed that patients with higher chromosome aberration frequencies had more severe acute toxicity. There was also a correlation between the number of translocations and the time course of the side effects of severe acute toxicity. There was also a correlation between the patients with higher chromosome aberration frequencies had more skin (22). It was also suggested that chromosome aberrations should be used to predict acute side effects (21).

In our study, we could not find extreme elevated radiosensitivity, i.e., chromosomal aberrations of the patient group were similar to chromosomal aberrations of healthy volunteers (Supplementary Figure S2). We showed multiple connections based on regression models between in vitro chromosome aberrations and pulmonary lung function test results (Figure 4 and Supplementary Table S3). Our data suggest that the chromosome aberration method has predictive value in assessing personal radiosensitivity during SBRT lung radiotherapy. To the best of our knowledge, our study is the first in attempting to prove this connection. As the method is cheap and easily adaptable to every laboratory, it can be a competitor to the highly expensive molecular genetic techniques. We detected multiple differences in the chromosome aberrations after in vitro irradiation in patients who later developed more than 20% decrease in their pulmonary function test at any time point of the follow-up. Most of the difference was found when we stratified the patients according to DLCO decrease. We also applied regression analysis, and most significant models we built applied the sum of dicentric and ring chromosomes as a predictor. Dicentrics and rings are chromosome aberrations specifically generated as a result of ionising radiation. We observed connections with the early (directly after radiotherapy and 3 months later) and late toxicities as well. We found the most connections at 6 months. The in vitro irradiation with 3 Gy was predictive in as many models as the CA values after 6 Gy (Supplementary Table S3). Borgman et al. found that higher dose was better for in vitro irradiation aiming at personal sensitivity assessment, but they described connections only with acute side effects (21).

We could find significant regression models of in vitro chromosomal aberrations predicting in vivo CAs (Figure 5 and Supplementary Table S4) in line with former studies (41, 42). To exclude the effect of volume, we normalised the in vitro CA data with the irradiated volume of the given patient. We did not use the size of the PTV because the lymphocytes can be damaged by the radiation anywhere in the irradiated field, not just in the PTV. The most frequent connections were again between the radiation-specific dicentrics and rings and other CAs.

We also observed significant differences in the total aberration value between baseline and 24- as well as 36-month time points (Figure 1). Seemingly, the aberrations did not clear out from the blood for 3 years. Similar results were published with micronucleus method after rectal cancer radiochemotherapy (42) and miscellaneous tumour entities (43) for 2 years and 19–75 months, respectively.

In conclusion, the lack of decrease of the absolute pulmonary function data shows that in our cohort, lung SBRT was a safe alternative of surgery in comorbid patients. However, in our cohort, the decrease of the relative pulmonary performance could be predicted by chromosome aberrations. Furthermore, we showed that there are more chromosome aberrations in the in vitro-irradiated blood (taken before radiotherapy) of the patients who later developed at least 20% relative pulmonary function loss. Our results can be suitable—after further study and validation—for prediction of individual radiosensitivity and pulmonary function decrease caused by chest irradiation.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Hungarian Ethical Committee, ETT TUKEB (23546-3/2017/EKU). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

ZK, GF, MK-G, and SG performed the laboratory experiments. TP and AH applied the in vitro tests. AB, KL, GO, and ZM performed follow-up. ZK, JL, and ZJ wrote the manuscript. ZT-N and CP supervised the work. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by the Hungarian Thematic Excellence Programme (TKP2020-NKA-26), the National Laboratories Excellence program (under the National Tumorbiology Fund).

REFERENCES

1. Smythe WR, American College of Chest P. Treatment of Stage I Non-Small Cell Lung Carcinoma. Chest (2003) 123(1 Suppl):181S–7S. doi: 10.1016/s0012-3692(15)32996-2
2. Spira A, Ettinger DS. Multidisciplinary Management of Lung Cancer. N Engl J Med (2004) 350(4):379–92. doi: 10.1056/NEJMra055336
3. McGarry RC, Song G, des Rosiers P, Timmerman R. Observation-Only Management of Early Stage, Medically Inoperable Lung Cancer: Poor Outcome. Chest (2002) 121(4):1155–8. doi: 10.1378/chest.121.4.1155
4. Nyman J, Johansson KA, Hulten U. Stereotactic Hypofractionated Radiotherapy for Stage I Non-Small Cell Lung Cancer—Mature Results for Medically Inoperable Patients. Lung Cancer (2006) 51(1):97–103. doi: 10.1016/j.lungcan.2005.08.011
5. Paludan M, Traberg Hansen A, Petersen J, Grau C, Hoyer M. Aggravation of Dysepsia in Stage I Non-Small Cell Lung Cancer Patients Following Stereotactic Body Radiotherapy: Is There a Dose-Volume Dependency? Acta Oncol (2006) 45(5):818–22. doi: 10.1080/0284186060915314
6. Grutters JP, Kessels AG, Pijls-Johannesma M, De Ruyscher D, Joore MA, Lambin P. Comparison of the Effectiveness of Radiotherapy With Photons, Protons and Carbon-Ions for Non-Small Cell Lung Cancer: A Meta-Analysis. Radiother Oncol (2010) 95(1):32–40. doi: 10.1016/j.radonc.2009.08.003
7. Lanni TB Jr, Grills IS, Kestin LL, Robertson JM. Stereotactic Radiotherapy Reduces Treatment Cost While Improving Overall Survival and Local Control Over Standard Fractionated Radiation Therapy for Medically Inoperable Non-Small-Cell Lung Cancer. Am J Clin Oncol (2011) 34(5):494–8. doi: 10.1097/CCO.0b013e3181ee63ae
8. Ohashi T, Takeda A, Shigematsu N, Kunieda E, Ishizaka A, Fukuda J, et al. Differences in Pulmonary Function Before vs. 1 Year After Hypofractionated Stereotactic Radiotherapy for Small Peripheral Lung Tumors. Int J Radiat Oncol Biol Phys (2005) 62(4):1003–8. doi: 10.1016/j.ijrobp.2004.12.050
9. Henderson M, McGarry R, Yiannoutsos C, Fakiris A, Hoopes D, Williams M, et al. Baseline Pulmonary Function as a Predictor for Survival and Decline in Pulmonary Function Over Time in Patients Undergoing Stereotactic Body Radiotherapy for the Treatment of Stage I Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys (2008) 72(2):404–9. doi: 10.1016/j.ijrobp.2007.12.051
10. Stanci S, Paulus R, Timmerman RD, Michalski JM, Barriger RB, Rejzak A, et al. No Clinically Significant Changes in Pulmonary Function Following Stereotactic Body Radiation Therapy for Early- Stage Peripheral Non-Small Cell Lung Cancer: An Analysis of RTOG 0236. Int J Radiat Oncol Biol Phys (2014) 88(5):1092–9. doi: 10.1016/j.ijrobp.2013.12.050
11. Stephens KL, Djemil T, Reddy CA, Gajdos SM, Kolar M, Machuzak M, et al. Comprehensive Analysis of Pulmonary Function Test (PFT) Changes After Stereotactic Body Radiotherapy (SBRT) for Stage I Lung Cancer in Medically Inoperable Patients. J Thorac Oncol (2009) 4(7):838–44. doi: 10.1097/JTO.0b013e3181a998f6
12. Azria D, Riou O, Castan F, Nguyen TD, Peignaux K, Lemanski C, et al. Radiation-Induced CD8 T-Lymphocyte Apoptosis as a Predictor of Breast Fibrosis After Radiotherapy: Results of the Prospective Multicenter French Trial. Ebiomedicine (2015) 2(12):1965–73. doi: 10.1016/j.ebiom.2015.10.024
13. Wang W, Xu Y, Schipper M, Matuszak MM, Ritter T, Cao Y, et al. Effect of Normal Lung Definition on Lung Dosimetry and Lung Toxicity Prediction in Radiation Therapy Treatment Planning. Int J Radiat Oncol Biol Phys (2013) 86(3):956–63. doi: 10.1016/j.ijrobp.2013.05.003
14. Tucker SL, Geara FB, Peters LJ, Brock WA. How Much Could the Radiotherapy Dose Be Altered for Individual Patients Based on a Predictive Assay of Normal-Tissue Radiosensitivity? Radiother Oncol (1996) 38(2):103–13. doi: 10.1016/0167-8140(95)01669-4
15. Bentzen SM. Potential Clinical Impact of Normal-Tissue Intrinsic Radiosensitivity Testing. Radiother Oncol (1997) 43(2):121–31. doi: 10.1016/0167-8140(97)01899-9
16. Bentzen SM, Tucker SL. Quantifying the Position and Steepness of Radiation Dose-Response Curves. Int J Radiat Biol (1997) 71(5):531–42. doi: 10.1080/095530097143860
17. Mackay RJ, Hendry JH. The Modelled Benefits of Individualizing Radiotherapy Patients’ Dose Using Cellular Radiosensitivity Assays With Inherent Variability. Radiother Oncol (1999) 50(1):67–75. doi: 10.1016/0167-8140(98)00132-7
18. Brock WA, Tucker SL. In Vitro Radiosensitivity and Normal Tissue Damage. Radiother Oncol (2000) 55(2):93–4. doi: 10.1016/0167-8140(00)00175-4
19. Hoeller U, Borgmann K, Bonacker M, Kuhlmeier A, Bajrovic A, Jung H, et al. Individual Radiosensitivity Measured With Lymphocytes may be Used to Predict the Risk of Fibrosis After Radiotherapy for Breast Cancer. Radiother Oncol (2003) 69(2):137–44. doi: 10.1016/j.radonc.2003.10.001
20. Lisowska J, Lankoff A, Wiecezorek A, Florak A, Kuszelewski T, Gozdz S, et al. Enhanced Chromosomal Radiosensitivity in Peripheral Blood Lymphocytes of Laboratory project (NLP-17)), and the National Research Development and Innovation Office under Grant [K-124937].

ACKNOWLEDGMENTS

The technical assistance of N. Vass and K. Kiss is greatly acknowledged.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.829972/full#supplementary-material
Larynx Cancer Patients. *Int J Radiat Oncol Biol Phys* (2006) 66(4):1245–52. doi: 10.1016/j.ijrobp.2006.07.1370

21. Borgmann R, Hoeltke K, Broockmeier S, Bernhard M, Roger P, Brackzook S, et al. Individual Radiosensitivity Measured With Lymphocytes may Predict the Risk of Acute Reaction After Radiotherapy. *Int J Radiat Oncol Biol Phys* (2008) 71(1):256–64. doi: 10.1016/j.ijrobp.2008.01.007

22. Huber R, Braselmann H, Geinitz H, Jachner E, Baumgartner A, Thamm R, et al. Chromosomal Radiosensitivity and Acute Radiation Side Effects After Radiotherapy in Tumour Patients–a Follow-Up Study. *Radiol Oncol* (2011) 47(1):7. doi: 10.1186/1748-717X-47-1

23. Dunst J, Neubauer S, Becker A, Gebhart E. Chromosomal in-Vitro Radiosensitivity of Lymphocytes in Radiotherapy Patients and AT-Homozgyotes. *Strahlenther Onkol* (1998) 174(10):510–6. doi: 10.1007/s0003883

24. Barber JB, Burrill W, Spreadborough AR, Levine E, Warren C, Kiltie AE, et al. Correlation Between In Vitro Chromosomal Radiosensitivity of Peripheral Blood Lymphocytes and the Expression of Normal Tissue Damage Following Radiotherapy for Breast Cancer. *Radiother Oncol* (2000) 55(2):179–86. doi: 10.1016/s0167-8140(99)00158-9

25. Slonina D, Klimek M, Szpytma T, Gasinska A. Comparison of the Radiosensitivity of Normal-Tissue Cells With Normal-Tissue Reactions After Radiotherapy. *Int J Radiat Biol* (2000) 76(9):1255–64. doi: 10.1080/09553000050134483

26. Lee TK, Allison RR, O’Brien KF, Johnke RM, Christie KJ, Naves JL, et al. Lymphocyte Radiosensitivity Correlated With Pelvic Radiotherapy Morbidity. *Int J Radiat Oncol Biol Phys* (2003) 57(1):222–9. doi: 10.1016/s0360-3016(03)00411-5

27. Widel M, Jedrus S, Lukaszczky B, Raczek-Szwyercyka K, Swierniak A. Radiation-Induced Micronucleus Frequency in Peripheral Blood Lymphocytes is Correlated With Normal Tissue Damage in Patients With Cervical Carcimoma Undergoing Radiotherapy. *Radiother Res* (2003) 159(6):713–21. doi: 10.1667/0033-7587(2003)159[0713:rmfipb]2.0.co;2

28. FinNon P, Kabacsi S, Mackay A, Raify C, A’Hern R, Owen R, et al. Correlation of In Vitro Lymphocyte Radiosensitivity and Gene Expression With Late Normal Tissue Reactions Following Curative Radiotherapy for Breast Cancer. *Radiother Oncol* (2012) 105(3):329–36. doi: 10.1016/j.radonc.2012.10.007

29. Fleming C, Cagney DN, O’Keefe S, Brennan SM, Armstrong JG, McClean B. Normal Tissue Considerations and Dose-Volume Constraints in the Moderately Hypofractionated Treatment of Non-Small Cell Lung Cancer. *Radiother Oncol* (2016) 119(3):423–31. doi: 10.1016/j.radonc.2016.03.013

30. Carrano AV, Natarajan AT. International Commission for Protection Against Environmental Mutagens and Carcinogens. ICPEMC Publication No. 14. Considerations for Population Monitoring Using Cytogenetic Techniques. *Mutat Res* (1988) 204(3):379–406. doi: 10.1016/0165-1218(88)90036-5

31. Motulsky HJ, Brown RE. Detecting Outliers When Fitting Data With Nonlinear Regression - a New Method Based on Robust Nonlinear Regression and the False Discovery Rate. *BMC Bioinf* (2006) 7:123. doi: 10.1186/1471-2105-7-123

32. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S, Roberge D, Lambert L, Bouchard M, et al. Excellent Cancer Outcomes Following Patient-Adapted Robotic Lung SBRT But a Case For Caution in Idiopathic Pulmonary Fibrosis. *Technol Cancer Res Treat* (2013) 14(6):667–76. doi: 10.7785/tcr.2012.500445

33. Schanne DH, Nestle U, Allgauer M, Andratschke N, Appold S, Dieckmann U, et al. Stereotactic Body Radiotherapy for Centrally Located Stage I NSCLC: A Multicenter Analysis. *Strahlenther Onkol* (2015) 191(2):125–32. doi: 10.1007/s00066-014-0739-5

34. Janvary ZL, Jansen N, Baart V, Devillers D, Lada C, et al. Clinical Outcomes of 130 Patients With Primary and Secondary Lung Tumors Treated With Cyberknife Robotic Stereotactic Body Radiotherapy. *Radiol Oncol* (2017) 51(2):178–86. doi: 10.1510/raon-2017-0015

35. Bahig H, Filion E, Vu T, Roberge D, Lambert L, Bouchard M, et al. Chromosomal Aberrations as SBRT Predictors of Local Control. *Radiother Oncol* (2018) 127(2):156–7. doi: 10.1016/j.radonc.2018.02.005

36. Bishawi M, Kim B, Moore WH, Bilfinger TV. Pulmonary Function Testing After Stereotactic Body Radiotherapy to the Lung. *Int J Radiat Oncol Biol Phys* (2012) 82(1):e107–110. doi: 10.1016/j.ijrobp.2011.01.037

37. Takeda A, Enomoto T, Sanuki N, Handa H, Aoki Y, Oku Y, et al. Reassessment of Declines in Pulmonary Function >=1 Year After Stereotactic Body Radiotherapy. *Chest* (2013) 145(1):130–7. doi: 10.1378/ chest.12-2027

38. Vorebitsova I, Darroudi F, Semyonov A, Kanayeva A, Timofeyeva N, Yakovleva T, et al. Analysis of Chromosome Aberrations by FISH and Giemsa Assays in Lymphocytes of Cancer Patients Undergoing Whole-Body Irradiation: Comparison of In Vivo and In Vitro Irradiation. *Int J Radiat Biol* (2001) 77(11):1123–31. doi: 10.1080/09553000010075527

39. Droge LH, Hennies S, Lorenzen S, Conradi LC, Quack H, Liersch T, et al. Prognostic Value of the Micronucleus Assay for Clinical Endpoints in Neoadjuvant Radiochemotherapy for Rectal Cancer. *BMC Cancer* (2021) 21(1):219. doi: 10.1186/s12885-021-02794-5

40. Lee TK, Allison RR, O’Brien KF, Naves JL, Karlsson UL, Wiley AL. Persistence of Micronuclei in Lymphocytes of Cancer Patients After Radiotherapy. *Radiat Oncol* (2002) 157(6):678–84. doi: 10.1046/j.1349-7006.2002.00799.x

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2022 Kocsis, Farkas, Bajcsay, Kan-Gazda, Lővy, Ostoros, Pócza, Herein, Ladiányi, Székely, Markóczy, Takács-Nagy, Polgár and Jurányi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*